The deal priced below last closing price of $2.55. ThinkEquity is acting as sole book running manager for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RNAZ:
- TransCode Therapeutics Announces Pricing of $8 Million Public Offering
- TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
- Transcode announces positive pre-clinical glioblastoma results with TTX-MC138
- Transcode Therapeutics files to sell common stock, no amount given
- Transcode announces first subject dosed in Phase 0 trial of TTX-MC138
